A multi-center, open-label, continuation trial LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02

Trial Profile

A multi-center, open-label, continuation trial LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 17 Jun 2017 Results of final 10 year data, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2017 According to a GlaxoSmithKline media release, results from the study have been presented at the Annual European Congress of Rheumatology (EULAR) 2017.
    • 16 Jun 2017 Results published in a GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top